Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
41.02
-1.94 (-4.52%)
At close: Jun 8, 2026, 4:00 PM EDT
41.08
+0.06 (0.15%)
After-hours: Jun 8, 2026, 7:59 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 96.82B DKK in the quarter ending March 31, 2026, with 23.99% growth. This brings the company's revenue in the last twelve months to 327.80B, up 8.13% year-over-year. In the year 2025, Novo Nordisk had annual revenue of 309.06B with 6.43% growth.
Revenue (ttm)
327.80B DKK
Revenue Growth
+8.13%
P/S Ratio
3.68
Revenue / Employee
4,716,207 DKK
Employees
69,505
Market Cap
186.16B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.06B | 18.66B | 6.43% |
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | 5.53B | 12.13% |
| Dec 31, 2008 | 45.55B | 3.72B | 8.90% |
| Dec 31, 2007 | 41.83B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Merck & Co. | 65.77B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Bristol-Myers Squibb Company | 48.48B |
NVO News
- 7 hours ago - Use of GLP-1 drugs early in pregnancy should not cause alarm - Reuters
- 12 hours ago - A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk. - The Motley Fool
- 14 hours ago - Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage - CNBC
- 16 hours ago - Novo Nordisk A/S - share repurchase programme - GlobeNewsWire
- 18 hours ago - Wegovy Prescription Milestone Achieved by Novo Nordisk (NVO) - GuruFocus
- 18 hours ago - Novo Nordisk Stock (NVO) Drops despite Obesity Updates as Eli Lilly Takes All the Shine - TipRanks
- 22 hours ago - Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch - WSJ
- 22 hours ago - Novo Nordisk's CagriSema 2.4 Mg Dose Shows Meaningful HbA1c And Weight Reduction Amid GI AEs - Nasdaq